AzTrials
AzTrials

Portal HypertensionNCT05789641

Multimodal Ultrasound and Portal Hypertension

An observational study of Portal Hypertension, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

According to international guidelines, Hepatic Venous Pressure Gradient is the gold standard technique for portal hypertension measurement, but it is invasive and poorly available. Currently, surveillance of oesophageal/gastric varices is performed by upper gastrointestinal endoscopy. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Portal Hypertension
How many people
73 participants
Where
1 siteItaly
Study dates
23 Mar 2020to Dec 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: adult cirrhotic patients

Who may be able to join

  • written informed consent
  • age more than 18 years
  • diagnosis of cirrhosis of different etiologies

Who cannot join

  • previous recent endoscopic treatment of oesophageal varices (<6 months)
  • portal and/or splanchnic thrombosis
  • portal cavernomatosis
  • acute or chronic heart failure
  • previous liver transplantation
  • presence of hepatocellular carcinoma or other hepatic neoplasms
Show all 9Show fewer
  • inadequate visualization of the liver parenchyma on B-mode ultrasound
  • known allergy to ultrasound contrast medium
  • pregnancy and lactation

Trial locations and contacts

1 site in 1 country.

Italy1 site, 1 recruiting
  • Fondazione Policlinico Gemelli IRCCS

    Roma, 00168

    MARIA ASSUNTA ZOCCO, PhD, 00393470597805

    Recruiting

Other trials in Italy

About this study

Official title: Role of Dynamic Contrast-enhanced Ultrasound (D-CEUS) and 2D Elastography in the Evaluation of Portal Hypertension and Risk of Oesophageal Variceal Bleeding in Patients With Liver Cirrhosis

According to international guidelines, Hepatic Venous Pressure Gradient is the gold standard technique for portal hypertension measurement, but it is invasive and poorly available. Currently, surveillance of oesophageal/gastric varices is performed by upper gastrointestinal endoscopy. More recently, non-invasive tools to estimate portal hypertension have been developed and, among them, ultrasound elastography has been proposed as a technique to stratify patient risk to have portal hypertension.

Aim of this study is to evaluate the relationship between ultrasound evaluation (D-CEUS + elastography) and endoscopic parameters predictive of clinically significant portal hypertension in patients with liver cirrhosis.

Read the detailed description

Background: About 80-90% of cirrhotic patients shows portal hypertension signs, including ascites, splenomegaly, oesophageal and/or gastric varices, encephalopathy. According to international guidelines, Hepatic Venous Pressure Gradient is the gold standard technique for portal hypertension measurement, but it is invasive and poorly available. Currently, surveillance of oesophageal/gastric varices is performed by upper gastrointestinal endoscopy. More recently, non-invasive tools to estimate portal hypertension have been developed and, among them, ultrasound elastography has been proposed as a technique to stratify patient risk to have portal hypertension. More specifically, liver stiffness <20kPa together with platelet count > 150.000/m3 (Baveno VI criteria) or > 100.000/mm3 (Expanded Baveno VI criteria) are considered at low risk of portal hypertension. D-CEUS provides information about microvascularization and it is widely used to characterize focal liver lesions, but recent data show its role also in evaluating the degree of liver fibrosis and portal hypertension.

Primary objective: To evaluate the relationship between ultrasound evaluation (D-CEUS + elastography) and endoscopic parameters predictive of clinically significant portal hypertension in patients with liver cirrhosis.

Secondary objectives:

  • To identify quantitative ultrasound parameters able to predict the presence of clinically significant portal hypertension.
  • To identify cut-off values of ultrasound parameters able to stratify the risk of bleeding in patients with oesophageal varices
  • To evaluate the relationship between the hemodynamic changes induced by endoscopic and/or pharmacological therapy of oesophageal varices highlighted with ultrasound (D-CEUS + elastography) and the hemodynamic changes highlighted by endoscopy.

Study design: Single-centre prospective observational study Methods: consecutive adult patients with liver cirrhosis needing to undergo endoscopic evaluation of portal hypertension will be enrolled in the Unit of Internal Medicine and Gastroenterology of the Policlinico Agostino Gemelli. Cirrhotic patients of different aetiologies will be included. Exclusion criteria will be previous recent endoscopic treatment of oesophageal varices (<6 months), portal and/or splanchnic thrombosis, portal cavernomatosis, acute or chronic heart failure, previous liver transplantation, presence of hepatocellular carcinoma or other hepatic neoplasms, inadequate visualization of the liver parenchyma on B-mode ultrasound, known allergy to ultrasound contrast medium, pregnancy and lactation. Assuming a disagreement rate of 5% between ultrasonographic and endoscopic diagnosis and considering an α=0.05 and a power of 90%, a sample size of N=73 patients is calculated. Patients will undergo ultrasound (B-mode, shear-wave elatography and D-CEUS) and endoscopic evaluation (diagnostic esophagogastroduodenoscopy plus endoscopic treatment of eosophageal or gastric varices, if needed) as per clinical practice. After obtaining informed consent, personal, clinical and laboratory data will be collected and analysed specifically for the study.

Medical subject headings
Hypertension, Portal

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. to evaluate the relationship between ultrasound and endoscopic parameters which predict clinically significant portal hypertension

    Measured: 3 months after endoscopic exam

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Mar 2023
  2. Study start23 Mar 2020
  3. Primary completionDec 2023 (estimated)
  4. Study completionDec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Retrospective
Enrolment
73 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05789641
Sponsor's protocol ID
2986
Status last verified
Aug 2023
First submitted
16 Mar 2023
Last updated
3 Aug 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Portal Hypertension, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 3 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Maria Assunta Zocco (00393470597805, mariaassunta.zocco@policlinicogemelli.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

to evaluate the relationship between ultrasound and endoscopic parameters which predict clinically significant portal hypertension (time frame: 3 months after endoscopic exam). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2023; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in